For those with confirmed growth hormone deficiency, the appropriate pathway remains referral to an NHS endocrinologist for formal assessment, biochemical testing, and, where indicated, initiation of licensed somatropin therapy under NICE TA188 criteria
Similarly, the oral GLP-1 RA will also need to demonstrate their cardiovascular safety in these populations (NCT05803421)
Our study provided additional data in the Chinese setting, complementing the previous evidence on once-weekly semaglutide versus sitagliptin of foreign populations, and provided insights to assist decision makers in choosing between the two drugs based on their value for money
The results are expected by the end of 2025, and if they confirm what the observational studies are suggesting, it could open up a whole new use case for GLP-1 medications in neurology
For twice-daily administration, administer in the AM and at bedtime